ARTICLE | Clinical News

Cayston aztreonam lysine regulatory update

February 20, 2012 8:00 AM UTC

The Scottish Medicines Consortium recommended against the use of Cayston aztreonam from Gilead on the National Health Service (NHS) in Scotland to treat chronic pulmonary Pseudomonas aeruginosa infections in adult patients with cystic fibrosis -- its approved indication. The consortium said there are limited data to support the sustainability of Cayston's short-term benefits over subsequent courses of treatment and that the company failed to present a sufficiently robust economic analysis. Cayston is delivered using the eFlow electronic nebulizer from Pari GmbH (Starnberg, Germany). ...